A Phase 1/2a Study Evaluating the Effects of ARO-MMP7 Inhalation Solution in Healthy Subjects and Patients with Idiopathic Pulmonary Fibrosis
Imagine a new inhaled medicine called ARO-MMP7. This study is like its first big test, checking if it's safe and how it works in people. It's for a serious lung condition called idiopathic pulmonary fibrosis (IPF), which makes your lungs scarred and makes it hard to breathe. Researchers want to see if this new medicine can help slow down or stop the scarring. Before giving it to people with IPF, they'll first test it in healthy volunteers to make sure it's safe. Then, they'll check how it affects people living with IPF. This is an early and important step in developing new treatments for IPF.
At a glance
What is this study about?
This study is designed to explore a new treatment called ARO-MMP7 in people who have a condition called idiopathic pulmonary fibrosis (IPF). IPF is a serious lung disease where the tissue in your lungs becomes scarred and thick, making it harder to breathe over time. We don't fully understand why it happens, and current treatments aim to slow down the disease rather than cure it.
The main goal of this study is to see if ARO-MMP7, which is given as an inhaled solution, is safe for people to use. It's also important to understand how the body handles this medicine and if it shows any signs of helping with IPF. This is an 'early stage' trial, meaning it's one of the first times this specific medicine is being tested in humans. Because of this, it's divided into two main parts: first, healthy volunteers will try the medicine to check for safety, and then people with IPF will receive it.
Finding new ways to treat IPF is very important, as it could offer hope for people living with this challenging condition. Every new treatment starts with these careful early studies to ensure safety and gather initial information about how well it might work.
Key takeaways
- This study is for a new inhaled medicine (ARO-MMP7) for Idiopathic Pulmonary Fibrosis (IPF).
- It's an early-stage study focusing on safety and how the medicine works.
- It will involve both healthy volunteers and people with IPF.
- The medicine is given by breathing it in.
- Participation involves regular clinic visits and health checks.
- You can stop participating at any time.
Who may be eligible?
To join this study, you need to be an adult, 18 years old or older. The study is open to both men and women.
Healthy volunteers will be checked to make sure they don't have any serious health problems that could make taking the medicine risky. For people with idiopathic pulmonary fibrosis (IPF), doctors will look at their specific diagnosis and other health information to make sure the study is a good fit for them.
There might be additional health requirements, like certain blood test results or how well your lungs are working, that the study doctors will go over with you. These details are important to keep participants safe and to make sure the study results are clear.
- Am I 18 years old or older?
- Do I have a confirmed diagnosis of Idiopathic Pulmonary Fibrosis (IPF)? (If applying as a patient)
- Am I generally healthy with no major ongoing illnesses? (If applying as a healthy volunteer)
- Am I able to attend regular clinic visits for assessments?
- Am I comfortable with taking an inhaled medicine?
This is a guide only — the research team will confirm whether you can take part.
What does participation involve?
If you decide to take part, you would first have a screening visit where doctors check your health to make sure you meet the study requirements. This might include a physical exam, blood tests, and checking your lung function.
During the study, you would receive the ARO-MMP7 medicine as an inhaled solution. This means you would breathe it in, similar to how some asthma medicines are taken. You would attend several study visits at a clinic. These visits are important for the research team to monitor your health, check for any side effects, and see how the medicine is affecting your body. They'll likely repeat some of the tests done at your screening visit, like blood tests and lung function tests. The exact number and duration of visits, as well as the total length of your participation, would be fully explained by the study team before you make any decisions.
Potential risks and benefits
Locations (3)
- —Spain
- —Denmark
- —Italy
Common questions
What is idiopathic pulmonary fibrosis (IPF)?
IPF is a serious lung disease where your lungs become scarred and stiff, making it hard to breathe. The word 'idiopathic' means we don't know the exact cause.
What does 'Phase 1/2a' mean for a study?
It means the study is in its early stages. Phase 1 focuses on safety in healthy people, and Phase 2a starts to look at safety and how well the medicine works in people with the condition.
How is the study medicine, ARO-MMP7, given?
The medicine is an 'inhalation solution,' which means you would breathe it in, similar to how some people use an inhaler for conditions like asthma.
Do I have to pay to be in this study?
No, you would not have to pay to participate in the study, and all study-related visits and treatments are usually provided at no cost to you.
Can I leave the study if I change my mind?
Yes, you are free to leave the study at any time, for any reason, and it will not affect your future medical care.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.